GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Movano Inc (NAS:MOVE) » Definitions » EBITDA Margin %

Movano (Movano) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Movano EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Movano's EBITDA for the three months ended in Dec. 2023 was $-5.98 Mil. Movano's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Movano's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Movano EBITDA Margin % Historical Data

The historical data trend for Movano's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Movano EBITDA Margin % Chart

Movano Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - - - -

Movano Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Movano's EBITDA Margin %

For the Medical Devices subindustry, Movano's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Movano's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Movano's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Movano's EBITDA Margin % falls into.



Movano EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Movano's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-29.532/0
= %

Movano's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-5.984/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Movano  (NAS:MOVE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Movano EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Movano's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Movano (Movano) Business Description

Traded in Other Exchanges
N/A
Address
6800 Koll Center Parkway, Pleasanton, CA, USA, 94566
Movano Inc is a health-focused technology company developing simple, smart, and personalized devices designed to help individuals on their health journey maintain good health today and prevent and manage chronic diseases in the future. It is developing a proprietary platform that uses Radio Frequency (RF) technology. It enables the creation of low-cost and scalable sensors that fit into wearable and other small form factors.
Executives
Jeremy Cogan officer: CFO 6800 KOLL CENTER PARKWAY, PLEASANTON CA 94566
Michael Aaron Leabman director, officer: CEO and President 207 VERITAS CT, SAN RAMON CA 94582
Emily Fairbairn director 10 ORINDA VIEW ROAD, ORINDA CA 94563
John Mastrototaro director 6800 KOLL CENTER PARKWAY, PLEASANTON CA 94566
Brian Cullinan officer: CFO 6800 KOLL CENTER PARKWAY, PLEASANTON CA 94566
Nan Kirsten Forte director 111 EIGHTH AVENUE, NEW YORK NY 10011
Ruben Caballero director C/O RESONANT INC. 10900 STONELAKE BLVD., SUITE 100, OFFICE 02-130, AUSTIN TX 78759
Dvine Irrevocable Trust 10 percent owner 6200 STONERIDGE MALL RD., SUITE 300, PLEASANTON CA 94588
Gregory S Tamkin 10 percent owner 303 RAY STREET, PLEASANTON CA 94566
Dorsey & Whitney Trust Co Llc 10 percent owner 401 EAST EIGHTH STREET, SUITE 319, SIOUX FALLS SD 57103
William Tai-wei Ho 10 percent owner C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016